GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » EV-to-EBITDA

Exact Therapeutics AS (OSL:EXTX) EV-to-EBITDA : -3.99 (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Exact Therapeutics AS's enterprise value is kr213.54 Mil. Exact Therapeutics AS's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was kr-53.54 Mil. Therefore, Exact Therapeutics AS's EV-to-EBITDA for today is -3.99.

The historical rank and industry rank for Exact Therapeutics AS's EV-to-EBITDA or its related term are showing as below:

OSL:EXTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.42   Med: 0   Max: 0
Current: -3.98

OSL:EXTX's EV-to-EBITDA is ranked worse than
100% of 446 companies
in the Biotechnology industry
Industry Median: 9.67 vs OSL:EXTX: -3.98

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-13), Exact Therapeutics AS's stock price is kr3.60. Exact Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was kr-1.660. Therefore, Exact Therapeutics AS's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Exact Therapeutics AS EV-to-EBITDA Historical Data

The historical data trend for Exact Therapeutics AS's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS EV-to-EBITDA Chart

Exact Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - -22.66 -7.42 -7.62 -7.37

Exact Therapeutics AS Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -7.62 - -7.37 -

Competitive Comparison of Exact Therapeutics AS's EV-to-EBITDA

For the Biotechnology subindustry, Exact Therapeutics AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Therapeutics AS's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Exact Therapeutics AS's EV-to-EBITDA falls into.



Exact Therapeutics AS EV-to-EBITDA Calculation

Exact Therapeutics AS's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=213.535/-53.541
=-3.99

Exact Therapeutics AS's current Enterprise Value is kr213.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Exact Therapeutics AS's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was kr-53.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exact Therapeutics AS  (OSL:EXTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Exact Therapeutics AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.60/-1.660
=At Loss

Exact Therapeutics AS's share price for today is kr3.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Exact Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was kr-1.660.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Exact Therapeutics AS EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Therapeutics AS Business Description

Traded in Other Exchanges
N/A
Address
Ostre Aker vei 19, Oslo, NOR, 0581
Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing Acoustic Cluster Therapy (ACT), a promising non-invasive precision health technology for targeted enhancement of therapeutics. ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS Headlines

No Headlines